<DOC>
	<DOCNO>NCT00130260</DOCNO>
	<brief_summary>This study continue evaluation immune response StaphVAX , Staphylococcus aureus type 5 8 capsular polysaccharide conjugate vaccine , end-stage renal disease patient , give 3rd 4th dose subset participant previous efficacy trial . Participants continue receive vaccine placebo blind manner , also randomly assign 1 2 different interval dos . The immunogenicity measure antibody blood , typical vaccine safety information also collect .</brief_summary>
	<brief_title>Evaluation Third Fourth Dose StaphVAXÂ® Adults With End-Stage Renal Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Participation prior study Nabi1371 Written inform consent Negative serum pregnancy test , appropriate Expect comply protocol procedure schedule Known HIV Immunomodulatory drug Malignancy ( basal cell squamous cell carcinoma , carcinoma situ cervix , early stage prostate cancer ) Active infection 2 week prior study injection Serious S. aureus infection within last 2 month prior injection Hypersensitivity component StaphVAX</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Staphylococcus aureus</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Randomized Controlled Trial</keyword>
</DOC>